Publication details

Efficacy, Safety, and Drug Survival During the First Year of Biologic Therapy for Psoriasis in Elderly Versus Younger Patients

Authors

SOBOTKOVA Tereza JAN Hugo SALAVEC Miloslav KOJANOVA Martina TICHY Martin NEČAS Miroslav MACHOVCOVA Alena CETKOVSKY Martin KYSILKA Zdenka TIVADAR Simona VACHATOVA Simona KUNESOVA Natalie BALÁŽ Monika PŘIKRYLOVÁ Pavlína ROB Filip

Year of publication 2025
Type Article in Periodical
Magazine / Source International Journal of Dermatology
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1111/ijd.17814
Keywords biological therapy; efficacy; elderly; psoriasis; safety
Description BackgroundOlder people represent an increasing proportion of patients treated with biologics for psoriasis. However, data availability is limited due to the underrepresentation of older patients in clinical trials.Materials and MethodsThis is a multicentric real-world observational study conducted in dermatology centers in the Czech Republic. It aims to compare the efficacy, safety, and drug survival of biologics in psoriasis patients aged >= 65 years with matched controls aged 18-64 years (1:2 ratio) during the first year of treatment. Data were extracted from the prospective BIOREP registry and patient medical records for adverse events (AEs).ResultsA total of 265 elderly patients and 530 matched controls were included. In both groups, a similar proportion of patients achieved a Psoriasis Area and Severity Index (PASI) <= 2 after 14 weeks (67% older vs. 63% younger adults), 26 weeks (71% vs. 76%), and 52 weeks (72% vs. 76%). During the first year of biologic therapy, at least one AE was reported in 108 (41%) older and 214 (40%) younger patients. Serious adverse events (SAEs) were reported in 13 (5%) older and 16 (3%) younger patients. Drug survival during the first year of therapy was lower in older (88%) compared to younger patients (96%), especially in those treated with adalimumab (81% vs. 99%).ConclusionThe efficacy of biological treatment was comparable between older and younger patients. Despite older people having more comorbidities, SAEs did not increase in this age group. Nonetheless, the survival rate of older patients was notably lower during the treatment period, especially when adalimumab was administered.

You are running an old browser version. We recommend updating your browser to its latest version.

More info